

CLAIMS

1. The use of C₆-C₁₀ linear, possibly branched, or cyclic hydrocarbon-chain n-alkanols, for preparing a 5 medicinal product for use in the treatment of pathology related to CFTR chloride channel disorders in humans or animals.

2. The use as claimed in claim 1, characterized 10 in that said n-alkanols are linear, possibly branched, hydrocarbon-chain n-alkanols in which the OH group is in the 1-position (primary alcohol) or in the 2-position (secondary alcohol).

15 3. The use as claimed in claim 1, characterized in that said n-alkanols are cyclic hydrocarbon-chain n-alkanols carrying one or more alcohol groups.

20 4. The use as claimed in any one of claims 1 to 3, characterized in that said pathologies are selected from the group consisting of cystic fibrosis, atypical cystic fibrosis, and obstructions of the bronchial tracts or of the digestive tracts.

25 5. The use as claimed in any one of claims 1 to 4, characterized in that said n-alkanols are provided in a form suitable for intranasal or buccal administration.

30 6. The use as claimed in claim 5, characterized in that said n-alkanols are provided in a liquid form, for administration in the form of an aerosol or in the form of a nebulized material.

35 7. The use as claimed in claim 6, characterized in that said n-alkanols are combined with at least one pharmaceutically acceptable carrier appropriate for said intranasal or buccal administration.

8. The use as claimed in any one of claims 1 to
7, characterized in that said n-alkanols are
administered at a concentration of between 0.001% and
5 0.1% (v/v), corresponding to a value of between 10 and
1000 ppm (parts per million), i.e. from 10 mg/kg to
1 g/kg.